US FDA approves Biocon Biologics’ YESINTEK for autoimmune diseases

Share it

YESINTEK works by targeting specific proteins that contribute to inflammation, offering a new treatment option for patients with these chronic autoimmune diseases.

Leave a Comment

Your email address will not be published. Required fields are marked *